| Name | Title | Contact Details |
|---|---|---|
Lisa Avellino |
Chief Information Officer | Profile |
One of every nine Americans is a member of an Anthem, Inc. affiliated health plan. For us, that`s a tremendous privilege and responsibility. Our focus every day is on improving the lives of the people we serve and the health of our communities. The foundation of our work can be summarized by: Delivering consistent service and becoming faster and simpler with every action we take. Creating the best health care value for our customers Investing where returns are the greatest to make the best use of our current assets. Being a market leader in each of our chosen businesses. Continuing to advocate for responsible health care reform.
Botanical Laboratories is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Ferndale, WA. To find more information about Botanical Laboratories, please visit www.botlab.com
Clinical Professionals is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.